KYTX logo

KYTXKyverna Therapeutics Inc.

$7.92
$0.00
(0.00%)
Pre-Market
Updated: 05:08 AM EDT·Prev Close $7.92
EarningsAug 12
Mkt Cap$495.48M
Vol87.00
32

Bearish Sentiment

How do you feel about KYTX?

News
all
press releases
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026?
Key PointsKyverna Therapeutics is a clinical-stage biopharmaceutical firm advancing cell therapies for autoimmune diseases...
Nasdaq News: Markets
News Placeholder
More News
News Placeholder
Kyverna Therapeutics Names Greg Martini CFO
(RTTNews) - Kyverna Therapeutics, Inc. (KYTX), Monday announced the appointment of Greg Martini as Chief Financial Officer, effective May 18...
Nasdaq News: Markets
News Placeholder
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Get Free Report) have received an average rating of 'Moderate Buy' from the five research firms that are covering the company, Marketbeat Ratings...
MarketBeat
News Placeholder
Kyverna Therapeutics (KYTX) to Release Earnings on Tuesday
Kyverna Therapeutics (NASDAQ:KYTX) will be releasing its Q1 2026 earnings before the market opens on Tuesday, May 12. (View Earnings Report at...
MarketBeat
News Placeholder
AIGH Capital Management LLC Acquires Shares of 1,500,000 Kyverna Therapeutics, Inc. $KYTX
AIGH Capital Management LLC purchased a new stake in shares of Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 1,500,000 shares of the company's stock, valued at approximately...
MarketBeat
News Placeholder
Kyverna Therapeutics Showcases miv-cel Data in SPS, gMG; CEO Eyes First Autoimmune CAR-T BLA
Kyverna Therapeutics (NASDAQ:KYTX) highlighted new clinical data for its CD19-directed autologous CAR T-cell therapy mivocabtagene autoleucel (miv-cel), formerly KYV-101, during an American Academy of Neurology (AAN) conference call focused on stiff person syndrome (SPS) and generalized myasthenia g...
MarketBeat
News Placeholder
Peapod Lane Capital LLC Decreases Holdings in Kyverna Therapeutics, Inc. $KYTX
Peapod Lane Capital LLC decreased its position in Kyverna Therapeutics, Inc. (NASDAQ:KYTX - Free Report) by 42.3% during the 4th quarter, according to its most recent disclosure with the SEC. The...
MarketBeat
News Placeholder
Kyverna Therapeutics' (KYTX) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Kyverna Therapeutics in a research note on Thursday...
MarketBeat
News Placeholder
Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up - Should You Buy?
Kyverna Therapeutics (NASDAQ:KYTX) Shares Gap Up - Should You Buy...
MarketBeat
News Placeholder
Why Kyverna Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket
Kyverna Therapeutics Inc (NASDAQ: KYTX) shares rose 25.8% in pre-market trading after positive trial results for miv-cel. Other gainers include HCAI, ELPW, and ALP.read more...
Benzinga
<
1
2
...
>

Advertisement|Remove ads.